WO2007043796A1 - Composition comprising the fraction of salviae miltiorrhizae radix for treating or preventing cognitive dysfunction and use thereof - Google Patents
Composition comprising the fraction of salviae miltiorrhizae radix for treating or preventing cognitive dysfunction and use thereof Download PDFInfo
- Publication number
- WO2007043796A1 WO2007043796A1 PCT/KR2006/004078 KR2006004078W WO2007043796A1 WO 2007043796 A1 WO2007043796 A1 WO 2007043796A1 KR 2006004078 W KR2006004078 W KR 2006004078W WO 2007043796 A1 WO2007043796 A1 WO 2007043796A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salviae miltiorrhizae
- bge
- diethyl ether
- cognitive function
- function disorder
- Prior art date
Links
- 230000003405 preventing effect Effects 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title abstract description 32
- 208000010877 cognitive disease Diseases 0.000 title description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 102
- 230000003920 cognitive function Effects 0.000 claims abstract description 25
- 230000006933 amyloid-beta aggregation Effects 0.000 claims abstract description 19
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims abstract description 18
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims abstract description 18
- 235000013402 health food Nutrition 0.000 claims abstract description 14
- 230000001988 toxicity Effects 0.000 claims abstract description 14
- 231100000419 toxicity Toxicity 0.000 claims abstract description 14
- 230000006907 apoptotic process Effects 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 11
- 230000007246 mechanism Effects 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims description 38
- 229960004132 diethyl ether Drugs 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 235000013361 beverage Nutrition 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 239000000287 crude extract Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 230000001055 chewing effect Effects 0.000 claims description 3
- 238000005194 fractionation Methods 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000002525 ultrasonication Methods 0.000 claims description 2
- 230000003389 potentiating effect Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 description 27
- 208000035475 disorder Diseases 0.000 description 18
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 235000013305 food Nutrition 0.000 description 11
- 241000207923 Lamiaceae Species 0.000 description 9
- 241000612118 Samolus valerandi Species 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- -1 methylene tanshinone Chemical compound 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010039966 Senile dementia Diseases 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000002781 deodorant agent Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 229930183118 Tanshinone Natural products 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 230000006974 Aβ toxicity Effects 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002439 beta secretase inhibitor Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003540 gamma secretase inhibitor Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- PBHFNBQPZCRWQP-QUCCMNQESA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-phenylcarbamate Chemical compound CN([C@@H]1[C@@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 PBHFNBQPZCRWQP-QUCCMNQESA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 238000010000 carbonizing Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940108366 exelon Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000020725 licorice root extract Nutrition 0.000 description 1
- 229940051810 licorice root extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940087380 vitamin b 12 0.2 mg Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- compositions containing present composition may be prepared in any form, such as oral dosage form (powder, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule), or topical preparation (cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like), or injectable preparation (solution, suspension, emulsion).
- oral dosage form prowder, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule
- topical preparation cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like
- injectable preparation solution, suspension, emulsion
- the inventive composition may additionally comprise one or more than one of organic acid, such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid; phosphate, such as phosphate, sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate; natural anti-oxidants, such as polyphenol, catechin, ⁇ - tocopherol, rosemary extract, vitamin C, green tea extract, licorice root extract, chitosan, tannic acid, phytic acid etc.
- organic acid such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid
- phosphate such as phosphate, sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate
- natural anti-oxidants such as polyphenol, catechin, ⁇ - tocopherol, rosemary extract, vitamin C, green tea extract, licorice root extract, chitosan, tannic acid, phytic acid etc.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a composition comprising diethyl ether soluble fraction of Salviae miltiorrhizae Bunge BGE showing potent treating and preventing activity of cognitive function disorder by the mechanism of inhibiting beta-amyloid aggregation as well as the toxicity and cell apoptosis caused by beta amyloid. Therefore it can be used as the therapeutics or health food for treating and preventing cognitive function disorder with safe.
Description
Description
COMPOSITION COMPRISING THE FRACTION OF SALVIAE
MILTIORRHIZAE RADIX FOR TREATING OR PREVENTING
COGNITIVE DYSFUNCTION AND USE THEREOF
Technical Field
[1] The present invention relates to a composition comprising the fraction of Salviae miltiorrhizae showing preventive and treating activity of cognitive dysfunction disease and the use thereof. Background Art
[2] CNS (Central Nervous System) consisting of brain and spinal cord which plays a main role in regulating life phenomenon is a essential organ governing all the human function through from sensory and (in)voluntary movement to thinking, memory, motion, language etc. Accordingly, a rapidly progressed apoptosis of neuronal cell caused by stroke, trauma etc as well as slowly progressed apoptosis such as degenerative disease occurring in CNS caused by senile dementia for example, Alzheimer disease or Parkinson disease etc result in irreversible functional disorder of neuronal network, which give rise to immortal failure of human function in the end. Among them, the patients suffering from Alzheimer disease, a representative senile dementia have been increased in proportion to both of extended life-span and modernized welfare facility. According to the public survey of Korea Institute for Health and Social Affair, the ratio of older people among Korean people exceeds 7% in 2000, reaches to 8.3% (3,970,000) and shall approach to 14.4% in 2019. Especially, the ratio of more than 65 years old patient suffering with senile dementia is presumed to 8.2% in Korea. In Western countries, about 10% among more than 65 years old and about 40-50% among 80 years old patient suffers with senile dementia. Since more than five million patients suffer with the disease, the medical expense caused thereby is presumed to hundred billion dollars in a year. There have been found that more than about two hundred thousand people are suffering from dementia in Korea. In America, it has been presumed the number of the patients be increased to two fold than the number of present patients in 2030 and fourteen million (more than 350%) in 2050.
[3] Since Alzheimer's disease initiated with cognitive function disorder is one of long- term degenerative diseases resulting in the breakdown of human nature, there have been tried to develop effective and preventive drugs till now, for example, acetylcholi- neesterase inhibitor such as Aricept® (Pfizer Co.), Exelon ®(Novartis Co.), Reiminyl ®(Yanssen Co.) or NMDA receptor antagonist such as Ebixa ®(Lundbeck Co.). However, the acetylcholineesterase inhibitor could just alleviate reduced cognitive
ability and could not satisfactorily treat etiological cause of the disease. Although the drug shows temporarily alleviated effect on only some of patients (about 40-50%), it could not maintain it's potency for a long time moreover it shows various adverse response such as hepato-toxicity, vomiting, anorexia in case of long-term treatment. Accordingly, there has been urgently needed to develop new therapeutic agent to prevent and treat the disease nowadays. Many multi-national pharmaceutical companies have been invested on the development in a large scale and in particular, focused in the development for beta- or gamma secretase inhibitor reducing the reproduced amount of beta-amyloid consisting of about 40 amino acids which has been presumed to be an etiological factor of Alzheimer disease. The basic study on the Alzheimer disease has been actively attempted in Korea however the development of Alzheimer treating agent has been merely progressed till now. Since there have been found in animal model test as well as clinical trial that the development of gamma secretase inhibitor is associated with considerable toxicity, it has been proved to be not recommendable whereas the development of beta secretase inhibitor is recommendable as proven by gene deficiency transformed animal model test. It is also regarded as a safe tool to focus on targeting the factors involved in beta amyloid aggregation. There has been reported that 'phenserine' developed by Axonyx Co. in USA has been progressed in Clinical trial 2 phase and it shows dual activities of inhibiting cholinesterase as well as beta amyloid aggregation (Greig et al., J. Med. Chem. 44 pp4062-4071, 2001; www,medicalnewstoday.com; www.alzforum.org/drg/drc)
[4] The development of vaccine using beta amyloid has been known as another possible method. There has been reported that the serial study on the vaccine progressed by Elan Co. failed because of its un-predictable adverse response such as encephalitis during clinical trial. However, it has been reported that beta amyloid vaccine could alleviate cognitive function in animal model test and improve the activity of brain cell as well as damaged brain neuronal cells, resulting in alleviating Alzheimer syndrome (Janus et al., Nature 408. pp979-982, 2000; Morgan et al., Nature 408. pp982-985, 2000)
[5]
[6] There have been reported that the extract of Salviae miltiorrhizae Bunge (Labiatae) can treat various disease, for example, abdominal pain, trauma, insomnia, skin rash etc and contains several diterpene quinine pigments belong to abietanoid compound, for example, tanshinone I, dihydrotanshinone I, tanshinone HA, tanshinone HB, methylene tanshinone etc. (Il-Moo Chang et al, Oriental Medicine and Medical Science Encyclopedia, Seoul National University, 2003).
[7] There have been also reported on the pharmacological activity of Salviae miltiorrhizae Bunge (Labiatae), for example, anti-oxidative activity (Yun-Hwa Kim,
Korean J. Soc. Food Cookery ScL, 19 p4, 2003), anti-cancer activity (Ok-Hee Kim, The Journal of Applied Pharmacology, 7, pp29-34, 1999), lowering effect on blood pressure (Korean Patent No. 10-0327894) etc. However, there has been not reported or disclosed about therapeutic effect on cognitive function disorder of the fraction of Salviae miltiorrhizae Bunge (Labiatae) in any of above cited literatures, the disclosures of which are incorporated herein by reference.
[8]
[9] To investigate an inhibiting effect of Salviae miltiorrhizae Bunge (Labiatae) on cognitive function disorder through already well-known screening tests, the inventors of the present invention have intensively screened various plants showing potent inhibiting activity of beta-amyloid aggregation and the toxicity caused by beta amyloid etc, and finally completed present invention by confirming that the specific fraction of Salviae miltiorrhizae Bunge (Labiatae) inhibits beta-amyloid aggregation as well as the toxicity and cell apoptosis caused by beta amyloid resulting in stimulating the proliferation of neuronal cells.
[10] These and other objects of the present invention will become apparent from the detailed disclosure of the present invention provided hereinafter.
[H]
Disclosure of Invention
Technical Problem
[12] Accordingly, it is an object of the present invention to provide a pharmaceutical composition comprising diethyl ether soluble fraction of Salviae miltiorrhizae Bunge BGE as an active ingredient in an effective amount to treat and prevent cognitive function disorder by the mechanism of inhibiting beta-amyloid aggregation as well as the toxicity and cell apoptosis caused by beta amyloid. Technical Solution
[13] In accordance with the present invention to provide a pharmaceutical composition comprising diethyl ether soluble fraction of Salviae miltiorrhizae Bunge BGE as an active ingredient and pharmaceutically acceptable carrier, diluents or adjuvants to treat and prevent cognitive function disorder.
[14] It is an object of the present invention to provide a method of treating or preventing cognitive function disorder in a mammal comprising administering to said mammal an effective amount of diethyl ether soluble fraction of Salviae miltiorrhizae Bunge BGE, together with a pharmaceutically acceptable carrier thereof.
[15] It is an object of the present invention to provide a use of diethyl ether soluble fraction of Salviae miltiorrhizae Bunge BGE for the manufacture of therapeutic agent for the treatment and prevention of cognitive function disorder by the mechanism of
inhibiting beta- amyloid aggregation as well as the toxicity and cell apoptosis caused by beta amyloid.
[16] The term "cognitive function disorder" disclosed herein includes Alzheimer type dementia, cerebrovascular type dementia, pick's disease, Creutzfeldt-jakob's disease, dementia caused by cephalic damage, Parkinson's disease, and so on, preferably, Parkinson's disease.
[17] The term "diethyl ether soluble extract of Salviae miltiorrhizae BGE" disclosed herein can be prepared by the steps consisting of: adding 0.1 to 0.2-fold volume of methanol to dried rhizoma of Salviae miltiorrhizae BGE; extracting with extraction method by the reflux extraction, or ultra-sonication extraction; subjecting the solution with filtering to obtain the supernatant to be concentrated with rotary evaporator, at the temperature ranging from 35 to 45 0C; drying to obtain dried crude extract powder of Salviae miltiorrhizae BGE at 1st step; Suspending said crude extract in distilled water and adding diethylether thereto; mixing and subjecting to fractionation with 3 to 6 times to obtain diethylether soluble fraction of Salviae miltiorrhizae BGE.
[18]
[19] In accordance with another aspect of the present invention, there is provided a pharmaceutical composition comprising diethyl ether soluble fraction of Salviae miltiorrhizae prepared by above described preparation method as an active ingredient in an effective amount to treat and prevent cognitive function disorder by the mechanism of inhibiting beta- amyloid aggregation as well as the toxicity and cell apoptosis caused by beta amyloid.
[20] It is an object of the present invention to provide a method of treating or preventing cognitive function disorder in a mammal comprising administering to said mammal an effective amount of diethyl ether soluble fraction of Salviae miltiorrhizae Bunge BGE prepared by above described preparation method, together with a pharmaceutically acceptable carrier thereof.
[21] It is an object of the present invention to provide a use of diethyl ether soluble fraction of Salviae miltiorrhizae Bunge BGE prepared by above described preparation method for the manufacture of therapeutic agent for the treatment and prevention of cognitive function disorder by the mechanism of inhibiting beta-amyloid aggregation as well as the toxicity and cell apoptosis caused by beta amyloid.
[22]
[23] The pharmaceutical composition of the present invention can contain about 0.01 ~
50 % by weight of the above extract based on the total weight of the composition.
[24]
[25] Through various screening test to determine inhibiting effect of diethyl ether fraction of Salviae miltiorrhizae Bunge (Labiatae) on cognitive function disorder, it
has confirmed that the diethyl ether fraction of Salviae miltiorrhizae Bunge (Labiatae) inhibits beta-amyloid aggregation as well as the toxicity and cell apoptosis caused by beta amyloid resulting in stimulating the proliferation of neuronal cells.
[26]
[27] The inventive composition for treating and preventing cognitive function disorder may comprises above extracts as 0.01 ~ 50 % by weight based on the total weight of the composition.
[28]
[29] The inventive composition may additionally comprise conventional carrier, adjuvants or diluents in accordance with a using method well known in the art. It is preferable that said carrier is used as appropriate substance according to the usage and application method, but it is not limited. Appropriate diluents are listed in the written text of Remington's Pharmaceutical Science (Mack Publishing co, Easton PA).
[30]
[31] Hereinafter, the following formulation methods and excipients are merely exemplary and in no way limit the invention.
[32]
[33] The composition according to the present invention can be provided as a pharmaceutical composition containing pharmaceutically acceptable carriers, adjuvants or diluents, e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil. The formulations may additionally include fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like. The compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a patient by employing any of the procedures well known in the art.
[34]
[35] For example, the compositions of the present invention can be dissolved in oils, propylene glycol or other solvents that are commonly used to produce an injection. Suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc., but are not limited to them. For topical administration, the extract of the present invention can be formulated in the form of ointments and creams.
[36]
[37] Pharmaceutical formulations containing present composition may be prepared in any form, such as oral dosage form (powder, tablet, capsule, soft capsule, aqueous
medicine, syrup, elixirs pill, powder, sachet, granule), or topical preparation (cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like), or injectable preparation (solution, suspension, emulsion).
[38]
[39] The composition of the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and also may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.
[40]
[41] The desirable dose of the inventive extract or composition varies depending on the condition and the weight of the subject, severity, drug form, route and period of administration, and may be chosen by those skilled in the art. However, in order to obtain desirable effects, it is generally recommended to administer at the amount ranging 10 g/kg, preferably, 1 to 3 g/kg by weight/day of the inventive extract or compounds of the present invention. The dose may be administered in single or divided into several times per day. In terms of composition, the amount of inventive extract should be present between 0.01 to 50% by weight, preferably 0.5 to 40% by weight based on the total weight of the composition.
[42]
[43] The pharmaceutical composition of present invention can be administered to a subject animal such as mammals (rat, mouse, domestic animals or human) via various routes. All modes of administration are contemplated, for example, administration can be made orally, rectally or by intravenous, intramuscular, subcutaneous, intracutaneous, intrathecal, epidural or intracerebroventricular injection.
[44]
[45] It is another object of the present invention to provide a health food or food additives comprising a diethyl ether fraction of Salviae miltiorrhizae BGE, together with a sitologically acceptable additive for the prevention and improvement of cognitive function disorder.
[46] The health food of the present invention comprises above extracts as 0.01 to 80 %, preferably 1 to 50 % by weight based on the total weight of the composition.
[47]
[48] Above health food can be contained in health food, health beverage etc, and may be used as powder, granule, tablet, chewing tablet, capsule, beverage etc.
[49]
[50] Also, the present invention provide a composition of the health food beverage for the prevention and improvement of cognitive function disorder adding above described extract 0.01 to 80 % by weight, amino acids 0.001 to 5 % by weight, vitamins 0.001 to
2 % by weight, sugars 0.001 to 20 % by weight, organic acids 0.001 to 10 % by weight, sweetener and flavors of proper amount.
[51]
[52] To develop for health food, examples of addable food comprising above extracts of the present invention are various food, beverage, gum, vitamin complex, health improving food and the like, and can be used as power, granule, tablet, chewing tablet, capsule or beverage etc.
[53]
[54] Also, the extract of the present invention will be able to prevent and improve blood circulatory disease by way of adding to child and infant food, such as modified milk powder, modified milk powder for growth period, modified food for growth period.
[55]
[56] Above described composition therein can be added to food, additive or beverage, wherein, the amount of above described extract in food or beverage may generally range from about 0.1 to 80w/w %, preferably 1 to 50 w/w % of total weight of food for the health food composition and 1 to 30 g, preferably 3 to 10 g on the ratio of IOOD of the health beverage composition.
[57]
[58] Providing that the health beverage composition of present invention contains above described extract as an essential component in the indicated ratio, there is no particular limitation on the other liquid component, wherein the other component can be various deodorant or natural carbohydrate etc such as conventional beverage. Examples of aforementioned natural carbohydrate are monosaccharide such as glucose, fructose etc; disaccharide such as maltose, sucrose etc; conventional sugar such as dextrin, cy- clodextrin; and sugar alcohol such as xylitol, and erythritol etc. As the other deodorant than aforementioned ones, natural deodorant such as taumatin, stevia extract such as levaudioside A, glycyrrhizin et al., and synthetic deodorant such as saccharin, aspartam et al., may be useful favorably. The amount of above described natural carbohydrate is generally ranges from about 1 to 20 g, preferably 5 to 12 g in the ratio of 100 D of present beverage composition.
[59]
[60] The other components than aforementioned composition are various nutrients, a vitamin, a mineral or an electrolyte, synthetic flavoring agent, a coloring agent and improving agent in case of cheese chocolate et al., pectic acid and the salt thereof, alginic acid and the salt thereof, organic acid, protective colloidal adhesive, pH controlling agent, stabilizer, a preservative, glycerin, alcohol, carbonizing agent used in carbonate beverage et al. The other component than aforementioned ones may be fruit juice for preparing natural fruit juice, fruit juice beverage and vegetable beverage,
wherein the component can be used independently or in combination. The ratio of the components is not so important but is generally range from about 0 to 20 w/w % per 100 w/w % present composition. Examples of addable food comprising aforementioned extract therein are various food, beverage, gum, vitamin complex, health improving food and the like.
[61]
[62] The inventive composition may additionally comprise one or more than one of organic acid, such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid; phosphate, such as phosphate, sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate; natural anti-oxidants, such as polyphenol, catechin, α- tocopherol, rosemary extract, vitamin C, green tea extract, licorice root extract, chitosan, tannic acid, phytic acid etc.
[63]
[64] The above fraction of Salviae miltiorrhizae BGE may be 20 to 90 % high concentrated liquid, power, or granule type.
[65]
[66] Similarly, the above extract of Salviae miltiorrhizae BGE can comprise additionally one or more than one of lactose, casein, dextrose, glucose, sucrose and sorbitol.
[67]
[68] Inventive extract of the present invention have no toxicity and adverse effect therefore; they can be used with safe.
[69]
[70] It will be apparent to those skilled in the art that various modifications and variations can be made in the compositions, use and preparations of the present invention without departing from the spirit or scope of the invention.
[71]
Advantageous Effects
[72] As described in the present invention, the diethyl ether soluble extract of Salviae miltiorrhizae Bunge (Labiatae) inhibits beta-amyloid aggregation as well as the toxicity and cell apoptosis caused by beta amyloid resulting in stimulating the proliferation of neuronal cells, Therefore, it can be used as the therapeutics or health food for treating and preventing cognitive function disorder without adverse action.
[73]
Brief Description of the Drawings
[74] The above and other objects, features and other advantages of the present invention will more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which;
[75]
[76] Fig. 1 shows the inhibition effect of the extract of Salviae miltiorrhizae BGE on beta amyloid aggregation and the cyotoxicity caused by beta amyloid.
Best Mode for Carrying Out the Invention
[77] The present invention is more specifically explained by the following examples.
However, it should be understood that the present invention is not limited to these examples in any manner.
[78] The following Reference Example, Examples and Experimental Examples are intended to further illustrate the present invention without limiting its scope.
[79]
[80] Example 1. Preparation of the diethyl ether soluble extract of Salviae miltiorrhizae
[81]
[82] 1-1. Preparation of methanol soluble extract
[83] 15kg of dried of Sαlviαe miltiorrhizae BGE purchased from Kyung-dong Market located in Seoul was cut into small pieces, mixed with 2.5 L of methanol and subjected to reflux-extraction for 3 hours at three times. The residue is filtered to obtain the supernatant and the filtrate was dried with vaccum evaporator at 4O0C to obtain 3.4kg of methanol soluble extract.
[84]
[85] 1-2. Preparation of diethyl ether soluble extract
[86] 3.4 kg of methanol soluble extract was suspended in distilled water and diethylether solvent was added thereto. The suspension was subject to fractionation at 3 to 4 times to obtain water soluble extract and diethyl ether soluble extract. The diethylether soluble extract was concentrated and dried to obtain 300g of diethyl ether soluble extract of Salviae miltiorrhizae BGE
[87]
[88] Experimental Example 1. Effect on beta amyloid
[89] 1-1. Inhibition of beta amyloid aggregation
[90] Synthetic beta amyloid 1-42 (BACHEM) was dissolved in DMSO in order to 250 μM solution and diluted with PBS into 1/10 on fluorescent black plate to induce aggregation. By comparing with inhibition activity of the diethyl ether extract prepared in Example 1 on beta amyloid aggregation, the test sample showing more than 50% inhibition activity was chosen to use and added to react for 1 hour at room temperature. ThT(Thioflavin T) was diluted with 5OmM glycine buffer solution and the diluted solution was added to each well by 150 μl. The absorbance was determined by microplate reader (SAFIRE, TECAN) at 450 nm excitation wavelength/480 nm
emission wavelength and the inhibition activity of the test sample on beta amyloid aggregation was transformed into IC .
[91] It has confirmed that the diethyl ether soluble extract of Salviae miltiorrhizae BGE showed potent inhibitory effect on beta amyloid aggregation (IC = 0.8 μl/ml).
[92] 1-2. Inhibition of beta amyloid toxicity
[93] HT 22 mouse neuronal cell line was incubated in DMEM (Dulbecco's Modified
Eagle's Medium, Gibco-BRL) medium supplemented with 10% FBS (Fetal Bovine Serum, Hy clone) and 1% penicillin/streptomycin (Sigma Co.) Prior to test, HT22 cell was incubated on 96 well plates with a density of 5x10 cell/well and further incubated in serum free DMEM medium for 1 hour before the treatment of test sample. Various concentration of diethyl ether extract prepared in Example 1 used as a test sample was added thereto and incubated for 1 hour. Aggregated beta amyloid (US peptide) was treated thereto to the concentration of 25mM and incubated for 18 hours to induce cell necrosis. 5mg/ml of MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) solution was added each well with 15 μl/well and the well was incubated for 4 hours. Dissolving buffer solution (10% SDS, 50%dimethyl formamide, pH 4.7) was added to each well with 100 μl/well and reacted for overnight. 18 hours after the reaction, the absorbance of solution was determined by microplate reader (SAFIRE, TECAN) at 570 nm/630 nm wavelength (Gillardon, F. et al., Brain Research, 706(D ppl69-172, 1996).
[94] As can be shown in Fig. 1, the diethyl ether soluble extract of Salviae miltiorrhizae
BGE showed potent inhibitory effect on beta amyloid toxicity at 100 D/D.
[95]
[96] 1-3. Determination of cytotoxicity
[97] To determine the toxicity of test sample, HT22 cell was incubated in accordance with similar method disclosed in 1-2 and various concentration of the test sample prepared in Example 1 was added to the cell to incubate for 18 hours. MTT solution and Dissolving buffer solution was added to cell serially and the absorbance was determined by microplate reader (SAFIRE, TECAN) at 570 nm.
[98] As can be shown in Fig. 1, it has been confirmed that the diethyl ether soluble extract of Salviae miltiorrhizae BGE showed no cytotoxicity comparing with the survival rate of control group (100%).
[99]
[100] Hereinafter, the formulating methods and kinds of excipients will be described, but the present invention is not limited to them. The representative preparation examples were described as follows.
[101]
[102] Preparation of powder
[103] Dried powder of Example 1 50mg
[104] Lactose lOOmg
[105] Talc lOmg
[106] Powder preparation was prepared by mixing above components and filling sealed package.
[107]
[108] Preparation of tablet
[109] Dried powder of Example 1 50mg
[110] Corn Starch lOOmg
[111] Lactose lOOmg
[112] Magnesium Stearate 2mg
[113] Tablet preparation was prepared by mixing above components and entabletting.
[114] Preparation of capsule
[115] Dried powder of Example 1 50mg
[116] Corn starch lOOmg
[117] Lactose lOOmg
[118] Magnesium Stearate 2mg
[119] Tablet preparation was prepared by mixing above components and filling gelatin capsule by conventional gelatin preparation method.
[120]
[121] Preparation of injection
[122] Dried powder of Example 1 50mg
[123] Distilled water for injection optimum amount
[124] PH controller optimum amount
[125] Injection preparation was prepared by dissolving active component, controlling pH to about 7.5 and then filling all the components in 2ml ample and sterilizing by conventional injection preparation method.
[126]
[127] Preparation of liquid
[128] Dried powder of Example 1 0.1~80g
[129] Sugar 5~ 1Og
[130] Citric acid 0.05-0.3%
[131] Caramel 0.005-0.02%
[132] Vitamin C 0.1-1%
[133] Distilled water 79-94%
[134] CO2 gas 0.5-0.82%
[135] Liquid preparation was prepared by dissolving active component, filling all the components and sterilizing by conventional liquid preparation method.
[136]
[137] Preparation of health food
[138] Extract of Example 1 lOOOmg
[139] Vitamin mixture optimum amount
[140] Vitamin A acetate 70mg
[141] Vitamin E l.Omg
[142] Vitamin B 0.13mg
[143] Vitamin B 0.15mg
[144] Vitamin B6 0.5mg
[145] Vitamin B 12 0.2mg
[146] Vitamin C lOmg
[147] Biotin lOmg
[148] Amide nicotinic acid 1.7mg
[149] Folic acid 50mg
[150] Calcium pantothenic acid 0.5mg
[151] Mineral mixture optimum amount
[152] Ferrous sulfate 1.75mg
[153] Zinc oxide 0.82mg
[154] Magnesium carbonate 25.3mg
[155] Monopotassium phosphate 15mg
[156] Dicalcium phosphate 55mg
[157] Potassium citrate 90mg
[158] Calcium carbonate lOOmg
[159] Magnesium chloride 24.8mg
[160] The above-mentioned vitamin and mineral mixture may be varied in may ways.
Such variations are not to be regarded as a departure from the spirit and scope of the present invention. [161]
[162] Preparation of health beverage
[163] Extract of Example 1 lOOOmg
[164] Citric acid lOOOmg
[165] Oligosaccharide lOOg
[166] Apricot concentration 2g
[167] Taurine Ig
[168] Distilled water 900D [169]
[170] Health beverage preparation was prepared by dissolving active component, mixing, stirred at 850C for 1 hour, filtered and then filling all the components in IOOOD ample
and sterilizing by conventional health beverage preparation method.
[171]
[172] The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims. Industrial Applicability
[173] As described in the present invention, the diethyl ether soluble extract of Salviae miltiorrhizae Bunge (Labiatae) inhibits beta-amyloid aggregation as well as the toxicity and cell apoptosis caused by beta amyloid resulting in stimulating the proliferation of neuronal cells, Therefore, it can be used as the therapeutics or health food for treating and preventing cognitive function disorder without adverse action.
[174]
Claims
[1] A pharmaceutical composition comprising diethyl ether soluble fraction of
Salviae miltiorrhizae Bunge BGE as an active ingredient in an effective amount to treat and prevent cognitive function disorder by the mechanism of inhibiting beta-amyloid aggregation as well as the toxicity and cell apoptosis caused by beta amyloid.
[2] The pharmaceutical composition according to claim 1 wherein said cognitive function disorder is selected from Alzheimer type dementia, cerebrovascular type dementia, pick's disease, Creutzfeldt-jakob's disease, dementia caused by cephalic damage or Parkinson's disease.
[3] The pharmaceutical composition according to claim 2 wherein said diethyl ether soluble extract of Salviae miltiorrhizae BGE is prepared by the steps consisting of: adding 0.1 to 0.2-fold volume of methanol to dried rhizoma of Salviae miltiorrhizae BGE; extracting with extraction method by the reflux extraction, or ultra- sonication extraction; subjecting the solution with filtering to obtain the supernatant to be concentrated with rotary evaporator, at the temperature ranging from 35 to 45 0C; drying to obtain dried crude extract powder of Salviae miltiorrhizae BGE at 1st step; Suspending said crude extract in distilled water and adding diethylether thereto; mixing and subjecting to fractionation with 3 to 6 times to obtain diethylether soluble fraction of Salviae miltiorrhizae BGE.
[4] A method of treating or preventing cognitive function disorder in a mammal comprising administering to said mammal an effective amount of diethyl ether soluble fraction of Salviae miltiorrhizae Bunge BGE, together with a pharmaceutically acceptable carrier thereof.
[5] A use of diethyl ether soluble fraction of Salviae miltiorrhizae Bunge BGE for the manufacture of therapeutic agent for the treatment and prevention of cognitive function disorder by the mechanism of inhibiting beta-amyloid aggregation as well as the toxicity and cell apoptosis caused by beta amyloid.
[6] A health food comprising diethyl ether soluble fraction of Salviae miltiorrhizae
Bunge BGE, together with a sitologically acceptable additive for the prevention and improvement of cognitive function disorder.
[7] The health food according to claim 6 wherein said health food is provided as powder, granule, tablet, chewing tablet, capsule or beverage type.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2005-0095657 | 2005-10-11 | ||
KR1020050095657A KR20070040209A (en) | 2005-10-11 | 2005-10-11 | Composition comprising the fraction of salviae miltiorrhizae radix for treating or preventing cognitive dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007043796A1 true WO2007043796A1 (en) | 2007-04-19 |
Family
ID=37942993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2006/004078 WO2007043796A1 (en) | 2005-10-11 | 2006-10-11 | Composition comprising the fraction of salviae miltiorrhizae radix for treating or preventing cognitive dysfunction and use thereof |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20070040209A (en) |
WO (1) | WO2007043796A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
CN101658601B (en) * | 2008-08-25 | 2012-09-05 | 上海中医药大学 | Chinese medicinal preparation for treatment or adjuvant treatment of Parkinson's diseases |
EP2411028A4 (en) * | 2009-03-27 | 2013-03-06 | Moleac Pte Ltd | Therapy for promoting cell growth |
WO2012134194A3 (en) * | 2011-03-29 | 2013-03-21 | Viromed Co., Ltd. | Herbal compositions for treating neurological diseases and improving memory impairment |
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
WO2021121528A1 (en) * | 2019-12-20 | 2021-06-24 | Clutch Cognition Aps | Nutraceutical composition for mental activity |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101729716B1 (en) | 2015-06-03 | 2017-04-24 | 원광대학교산학협력단 | A composition for prevent or treatmen of neurodegerative diseases |
KR102371285B1 (en) * | 2018-05-10 | 2022-03-08 | 주식회사 헬릭스미스 | Herbal Composition For Treating Attention Deficit Hyperactivity Disorder |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100341368B1 (en) * | 1999-08-18 | 2002-06-21 | 김춘란 | Treatment of cardio- vascular disease and Its process |
KR20030091465A (en) * | 2002-05-28 | 2003-12-03 | 학교법인 경희대학교 | Composition comprising an extract of Salviae Miltiorrhizae BGE having neuro-protective activity |
WO2003099759A1 (en) * | 2002-05-23 | 2003-12-04 | Tianjin Tasly Pharmaceutical Co., Ltd. | Preparation and application of transhintotalphenolic acid |
KR20040000615A (en) * | 2002-06-22 | 2004-01-07 | 박래길 | Extract of Radix Salviae miltiorrhizae and Rhizoma Cnidii which inhibit apoptotic neural cell death |
WO2004012651A2 (en) * | 2002-07-31 | 2004-02-12 | Tianjin Tasly Pharmaceutical Co., Ltd., China | Composition for heart disease, method to prepare same and uses thereof |
WO2004084884A1 (en) * | 2003-03-24 | 2004-10-07 | The Chinese University Of Hong Kong | Use of tanshinone derivates as cholinesterase inhibitors in treating related diseases |
-
2005
- 2005-10-11 KR KR1020050095657A patent/KR20070040209A/en not_active Application Discontinuation
-
2006
- 2006-10-11 WO PCT/KR2006/004078 patent/WO2007043796A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100341368B1 (en) * | 1999-08-18 | 2002-06-21 | 김춘란 | Treatment of cardio- vascular disease and Its process |
WO2003099759A1 (en) * | 2002-05-23 | 2003-12-04 | Tianjin Tasly Pharmaceutical Co., Ltd. | Preparation and application of transhintotalphenolic acid |
KR20030091465A (en) * | 2002-05-28 | 2003-12-03 | 학교법인 경희대학교 | Composition comprising an extract of Salviae Miltiorrhizae BGE having neuro-protective activity |
KR20040000615A (en) * | 2002-06-22 | 2004-01-07 | 박래길 | Extract of Radix Salviae miltiorrhizae and Rhizoma Cnidii which inhibit apoptotic neural cell death |
WO2004012651A2 (en) * | 2002-07-31 | 2004-02-12 | Tianjin Tasly Pharmaceutical Co., Ltd., China | Composition for heart disease, method to prepare same and uses thereof |
WO2004084884A1 (en) * | 2003-03-24 | 2004-10-07 | The Chinese University Of Hong Kong | Use of tanshinone derivates as cholinesterase inhibitors in treating related diseases |
Non-Patent Citations (4)
Title |
---|
CHAN K. ET AL.: "Protective effects of Danshensu from the aqueous extract of Salvia miltiorrhia (Danshen) against homocysteine-induced endothelial dysfunction", LIFE SCI., vol. 75, no. 26, 2004, pages 3157 - 3171, XP004601757 * |
LI L.X. ET AL.: "Effects of tanshinone on neuropathological changes induced by amyloid beta-peptide(1-40) injection in rat hippocampus", ACTA PHARMACOL. SIN., vol. 25, no. 7, 2004, pages 861 - 868, XP003012376 * |
REN Y. ET AL.: "Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorrhiza", PLANTA MED., vol. 70, no. 3, 2004, pages 201 - 204, XP003012375 * |
SATO M. ET AL.: "Modulating effect of tanshinones on mutagenic activity of Trp-P-1 and benzo[pyrene] in Salmonella typhimurium", MUTAT. RES., vol. 265, no. 2, 1992, pages 149 - 154, XP003012376 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
CN101658601B (en) * | 2008-08-25 | 2012-09-05 | 上海中医药大学 | Chinese medicinal preparation for treatment or adjuvant treatment of Parkinson's diseases |
EP2411028A4 (en) * | 2009-03-27 | 2013-03-06 | Moleac Pte Ltd | Therapy for promoting cell growth |
US9289459B2 (en) | 2009-03-27 | 2016-03-22 | Moleac Pte. Ltd. | Therapy for promoting cell growth |
US10188688B2 (en) | 2009-03-27 | 2019-01-29 | Moleac Pte. Ltd. | Therapy for promoting cell growth |
WO2012134194A3 (en) * | 2011-03-29 | 2013-03-21 | Viromed Co., Ltd. | Herbal compositions for treating neurological diseases and improving memory impairment |
KR20130130069A (en) * | 2011-03-29 | 2013-11-29 | 주식회사 바이로메드 | Herbal compositions for treating neurological diseases and improving memory impairment |
JP2014510752A (en) * | 2011-03-29 | 2014-05-01 | バイロメッド カンパニー リミテッド | Herbal medicine composition for treatment of neurological disorders and improvement of memory loss |
KR101601860B1 (en) * | 2011-03-29 | 2016-03-09 | 주식회사 바이로메드 | Herbal Compositions for Treating Neurological Diseases and Improving Memory Impairment |
US10058583B2 (en) | 2011-03-29 | 2018-08-28 | Viromed Co., Ltd. | Herbal compositions for treating neurological diseases and improving memory impairment |
WO2021121528A1 (en) * | 2019-12-20 | 2021-06-24 | Clutch Cognition Aps | Nutraceutical composition for mental activity |
Also Published As
Publication number | Publication date |
---|---|
KR20070040209A (en) | 2007-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090312413A1 (en) | Composition Comprising Tanshinone Compounds Isolated From The Extract Of Salviae Miltiorrhizae Radix For Treating Or Preventing Cognitive Dysfunction And The Use Thereof | |
WO2007043796A1 (en) | Composition comprising the fraction of salviae miltiorrhizae radix for treating or preventing cognitive dysfunction and use thereof | |
KR20070054915A (en) | Composition comprising flavone type flavonoid for treating and preventing cognitive dysfunction | |
KR101077523B1 (en) | A composition comprising the extract of crude drug selected from Eriobotryae Folium and Dendropanax morbiferafor treating and preventing neuro-degenerative disease | |
KR20120033633A (en) | Composition comprising the curcumin for bone growth-promoting effects | |
JP2008528481A (en) | Composition comprising a complex herbal extract having neuroprotective activity for the prevention and treatment of stroke and neurodegenerative diseases | |
KR101793503B1 (en) | Composition for prevention or treatment of neurodegenerative diseases | |
KR20160115889A (en) | Composition for prevention, improvement or treatment of osteoporosis comprising extract of Sigesbeckia spp. | |
KR101569813B1 (en) | Composition for preventing or treating brain disease or neural disease comprising oriental herbal extracts | |
KR20160045257A (en) | A composition comprising an extract of Hippophae rhamnoides for improving physical fatigue, and exercise performance ability | |
WO2008044848A1 (en) | A composition comprising an extract of rhei rhizoma or physcion compound isolated therefrom for treating or preventing cognitive dysfunction and the use thereof | |
KR100692402B1 (en) | A pharmaceutical composition comprising the extract of gardenia for treating or preventing depression disease | |
KR101502465B1 (en) | A pharmaceutical composition comprising Alpinia Officinarum extracts for prevention and treatment of bone diseases or anti-vascular calcification activity | |
KR102242400B1 (en) | Functional Food for preventing Composition for preventing inflammatory disease due to stress | |
WO2008007880A1 (en) | A composition comprising an extract of prunus persica (l.) batsch for treating and preventing bone diseases | |
KR101972657B1 (en) | Composition comprising extract of Angelica decursiva Franchet et Savatieras or compounds isolated therefrom for preventing or treating osteoporosis | |
KR101077522B1 (en) | A composition comprising the extract of Eriobotryae Folium for treating and preventing neurodegenerative disease | |
KR101793692B1 (en) | Composition for preventing or treating of neurological disorder comprising maackiain | |
KR20150043867A (en) | Composition for preventing or treating brain disease or neural disease comprising oriental herbal extracts | |
KR101654977B1 (en) | Anti-obesitic composition comprising kirenol or extract of Sigesbeckia orientalis L. | |
KR102599530B1 (en) | A composition for weight control comprising benzopyran | |
KR101468288B1 (en) | Pharmaceutical composition for prevention or treatment of Parkinson's disease comprising Eucommiae ulmoides extract or fraction thereof | |
KR102151643B1 (en) | Composition comprising extract of Lentinula edodes for prevention or treatment of bone diseases | |
KR102448913B1 (en) | Composition comprising extract of Abeliophyllum distichum for prevention or treatment of bone diseases | |
KR102191588B1 (en) | Composition for Preventing or Treating Cognitive Dysfunction Comprising Extraction of Gentiana lutea or Compound Isolated therefrom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06799158 Country of ref document: EP Kind code of ref document: A1 |